Poster presentations: Treatment

20 Posters

Effects of smoking on lymphocyte subpopulations in patients with MS on dimethyl fumarate

Young Investigator
Maria-Elizabeth Baeva
Vancouver, Canada

Delayed and recurrent dimethyl fumarate induced-lymphopenia in patients with Multiple Sclerosis.

Young Investigator
Serena Borrelli
Brussels, Belgium

Rituximab in Multiple Sclerosis: B-lymphocyte population study and its relationship with dosing regimen

Young Investigator
Inês Cunha
Coimbra, Portugal

Cladribine: 14 years brain atrophy and clinical follow-up

Dominique Dive
Esneux, Belgium

Assessing the real-world effectiveness of ocrelizumab in patients with multiple sclerosis – CONFIDENCE one-year interim analysis

Young Investigator
Julius Eggebrecht
Grenzach-Wyhlen, Germany

Safety and tolerability in patients with multiple sclerosis receiving ocrelizumab in a real-world setting – CONFIDENCE one-year interim analysis

Young Investigator
Julius Eggebrecht
Grenzach-Wyhlen, Germany

Secondary Autoimmune Diseases following Ocrelizumab Therapy for Multiple Sclerosis

Young Investigator
Sophie Elands
Brussels, Belgium

Long-term efficacy and safety of ponesimod: Results from randomized phase II core and extension studies in relapsing remitting multiple sclerosis

Mark S. Freedman
Ottawa, Canada

Therapeutic Plasma Exchange Effect on Neuromyelitis Optica Spectrum Disorder

Young Investigator
Enrique Gomez-Figueroa
Mexico City, Mexico

Propensity-matched comparison of early intensive and escalation treatment strategy in Finnish MS patients

Young Investigator
Katariina Hänninen
Turku, Finland

Effect of oral ponesimod on clinical disease activity and MRI-based outcomes in patients with relapsing multiple sclerosis: Phase 3 OPTIMUM study

Ludwig Kappos
Basel, Switzerland

Safety and immune cell and immunoglobulin levels with evobrutinib, a Bruton’s tyrosine kinase inhibitor, in relapsing multiple sclerosis: results of an open-label extension to a Phase II study

Xavier Montalban
Barcelona, Spain

Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting

Young Investigator
Huah Shin Ng
Vancouver, Canada

Inhalation of Dimethyl Fumarate encapsulated-nanoparticles attenuates clinical signs and central nervous system inflammation of Experimental Autoimmune Encephalomyelitis animals’ models

Winner Young Investigator Award
Young Investigator
Bárbara Pinto
Belo Horizonte, Brazil

Characterization of cladribine tablets treated MS patients in Finland

Young Investigator
Ilkka Rauma
Tampere, Finland

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis in DAYBREAK: an open-label extension study of ozanimod phase 1−3 trials

Krzysztof Selmaj
Olsztyn, Poland

Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders

Decai Tian
Beijing, China

Phase I study of ATA188, an off-the-shelf, allogeneic Epstein-Barr virus-targeted T-cell immunotherapy for progressive forms of multiple sclerosis

Jonathan Willmer
South San Francisco, California, United States

Real-world demographics, clinical characteristics and treatment patterns in relapsing multiple sclerosis patients on disease-modifying therapy (encore abstract from ACTRIMS/ECTRIMS)

Tjalf Ziemssen
Dresden, Germany

Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: A Model-Based Meta-Analysis for Annualized Relapse Rate

Matthew Zierhut
San Diego, United States